AYA

Artrya Wins FDA Clearance to Advance Rollout of Salix Coronary Plaque Module

Artrya (ASX: AYA) has received clearance from the US Food and Drug Administration for its Salix Coronary Plaque module. The regulatory milestone enables the company to charge per-scan fees in its largest market, significantly enhancing revenue potential. The approval follows Artrya’s recent US launch and builds on momentum established with its Salix Coronary Anatomy platform. […]